Phenotypic differences between apolipoprotein e genetic subgroups: Research and clinical implications

Alzheimer's Research and Therapy

Volumn 4, Issue 3, 2012, Pages

  Caselli, Richard J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID; APOLIPOPROTEIN E4; BAPINEUZUMAB; LEVODOPA; TAU PROTEIN;

ALZHEIMER DISEASE; BRAIN HEMORRHAGE; COGNITIVE DEFECT; EDEMA; GENE DOSAGE; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MENINGOENCEPHALITIS; MILD COGNITIVE IMPAIRMENT; NONHUMAN; PARKINSON DISEASE; PERSONALIZED MEDICINE; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; VASCULAR DISEASE; VASOGENIC EDEMA;

EID: 84862280789     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt123     Document Type: Review

References (15)

1. Gene dose of apolipoprotein E type 4 allele and the risk of AD in late onset families. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA, Science 1993 261 921 923 10.1126/science.8346443 8346443 (Pubitemid 23275809)
2. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN, Kokmen E, Waring SC, Kurland LT, JAMA 1995 273 1274 1278 10.1001/jama.1995.03520400044042 7646655
3. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, Baxter LC, Rapcsak SZ, Shi J, Woodruff BK, Locke DE, Snyder CH, Alexander GE, Rademakers R, Reiman EM, N Engl J Med 2009 361 255 263 10.1056/NEJMoa0809437 19605830
4. Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE e4 allele. van der Flier WM, Pijnenburg YAL, Fox NC, Scheltens P, Lancet Neurol 2011 10 280 288 10.1016/S1474-4422(10)70306-9 21185234
5. Apolipoprotein E genotypes in a neuropathological series from the Consortium to Establish a Registry for Alzheimer's Disease. Welsh-Bohmer KA, Gearing M, Saunders AM, Roses AD, Mirra S, Ann Neurol 1997 42 319 325 10.1002/ana.410420308 9307253 (Pubitemid 27391115)
6. APOE e2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Berlau DJ, Corrada MM, Head E, Kawas CH, Neurology 2009 72 829 834 10.1212/01.wnl.0000343853.00346.a4 19255410
7. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT, Ann Neurol 1995 38 254 259 10.1002/ana.410380219 7654074
8. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW, Lancet Neurol 2011 10 785 796 10.1016/S1474-4422(11)70156-9 21802369
9. Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment. Whitehair DC, Sherzai A, Emond J, Raman R, Aisen PS, Petersen RC, Fleisher AS, Alzheimer's Disease Cooperative Study, Alzheimers Dement 2010 6 412 419 10.1016/j.jalz.2009.12.003 20813342
10. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Poirer J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri M, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, Gauthier S, Proc Natl Acad Sci USA 1995 92 12260 12264 10.1073/pnas.92.26.12260 8618881 (Pubitemid 26014050)
11. Subacute meningoencephalitis in a subset of patients with AD after AB42 immunization. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C, Neurology 2003 61 46 54 10.1212/01.WNL.0000073623.84147.A8 12847155 (Pubitemid 36818745)
12. Long-term effects of AB42 immunisation in Alzheimer's disease: follow-up of a randomized, placebo-controlled phase 1 trial. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA, Lancet 2008 372 216 223 10.1016/S0140-6736(08)61075-2 18640458 (Pubitemid 351978111)
13. Consequence of AB immunization on the vasculature of human Alzheimer's disease brain. Boche D, Zotova E, Weller RO, Love S, Neal JW, Pickering RM, Wilkinson D, Holmes C, Nicoll JAR, Brain 2008 131 3299 3310 10.1093/brain/awn261 18953056
14. Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, Sabbagh M, Honig LS, Posteinsson AP, Leiberburg I, Arrighi HM, Morris KA, Lu Y, Liu E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M, Lancet Neurol 2012 11 241 249 10.1016/S1474-4422(12)70015-7 22305802
15. 11C-PiB PET assessment of change in fibrillar amyloid-B load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double blind, placebo-controlled, ascending dose study. Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, de Llano SRM, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M, Lancet Neurol 2010 9 363 372 10.1016/S1474-4422(10)70043-0 20189881